"To every thing there is a season..." this is the time to patiently wait.

My greatest concern is that management has it's priorities in order, a most difficult task with limited resources and all that RVX has on it's plate. I would hope that the trial recruitment and design continues to be managed and tweaked with meticulous detail. Recruiting 2400 patients given the inclusion criteria as specified to test the drug and reach a favorable primary outcome under narrowly defined MACE is an onerous task.

IMHO the Q1 webcast will most likely fall short of the expectations displayed on this board. Favorable trial resuts and proof of a marketable product shoud be the top priority. The trial is funded. The trial will take time. If the endpoints are not reached this time its all over. This small company has a rather long list of goals yet to achieve and must be careful not to get the cart before the horse. Remarkable achievements have been made in funding the BetonMace trial, securing patents, developing hundreds of compounds, attracting world class talent....they now need clinical proof that RVX is a viable and marketable therapy. Refinancing the Credit Line in a nondilutive transaction should not be a problem if the trial meets the midpoint safety standards. A Nasdaq listing presently is a catch 22 prospect and what good is it without a marketable product? Management needs time to concentrate on the job at hand and reach a favorable trial conclusion.

Long and Strong

Chicagoest